Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Olutasidenib Single Agent as Maintenance Therapy in IDH1mut AML After Induction and Consolidation

NCT07130695 is registered in ClinicalTrials.gov with Virginia Commonwealth University as lead sponsor.

NCT NCT07130695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07130695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Olutasidenib Single Agent as Maintenance Therapy in IDH1mut AML After Induction and Consolidation
Lead sponsor
Virginia Commonwealth University
Phase
Phase 1
Overall status
Recruiting
Start date
February 2, 2026
Completion date
October 31, 2030
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia